Results 121 to 130 of about 64,978 (265)

A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial. [PDF]

Cancers (Basel)
Pirosa MC, Hess D, Krasniqi F, Novak U, Mach N, Zenz T, Holer L, Cascione L, Cannas E, Rinaldi A, Schär S, Zucca E, Bertoni F, Stathis A, Swiss Group for Clinical Cancer Research SAKK.   +14 more
europepmc   +1 more source

Low-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature. [PDF]

Front Oncol
Peng G, Wang X, Dai M.
europepmc   +1 more source

Prognostic impact of blood Epstein–Barr virus‐DNA in patients with peripheral T‐cell lymphoma, not otherwise specified

British Journal of Haematology, EarlyView.
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon, Hyungwoo Cho, In Hye Song, Sejin Kim, So Heun Lee, Kyoungmin Lee, Shin Kim, Chan‐Sik Park, Eun Jin Chae, Kyung Won Kim, Jin‐Sook Ryu, Sang‐Wook Lee, Jaewon Hyung, Heounjeong Go, Dok Hyun Yoon   +14 more
wiley   +1 more source

A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma. [PDF]

Clin Cancer Res
Strati P, Feng L, Tyshevich A, Shavronskaya D, Alesse J, English N, Sheehan E, Syzrantsev N, Nesmelov A, Zhuang TZ, Chihara D, Westin JR, Ahmed S, Fayad LE, Henderson J, Dent K, McChesney E, Neelapu SS, Flowers CR.   +18 more
europepmc   +1 more source

Comorbid conditions after allogeneic haematopoietic stem cell transplantation in young adults in Germany—A prospective, multicentre trial

British Journal of Haematology, EarlyView.
Summary Young adults (YA) are particularly affected by comorbid conditions following allogeneic haematopoietic stem cell transplantation (alloHSCT), as they have to live with them for many years. This is the first multicentre prospective study investigating sequelae after alloHSCT in YA in Germany. In total, 107 patients who survived relapse‐free until
Pauline Rocke, Lena Tandetzky, Daniel Wolff, Katharina Egger‐Heidrich, Daniela Heidenreich, Kerstin Schaefer‐Eckart, Eva Wagner‐Drouet, Jochen J. Frietsch, Andreas Hochhaus, Inken Hilgendorf   +9 more
wiley   +1 more source

Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL). [PDF]

Clin Cancer Res
Hodson DJ, Shouse G, Shin HJ, Salar A, Bobillo S, Ribrag V, Macpherson NA, Cordoba R, Kim JS, Guidez S, Herrera AF, Morschhauser F, Colton D, Izuzquiza M, Sambamurthy N, Munugalavadla V, Vicente S, Gorgun G, Chen R, Younes A, Wang ML.   +20 more
europepmc   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study. [PDF]

Cancer Sci
Izutsu K, Fukuhara N, Yuda J, Suehiro Y, Kusumoto S, Casadebaig ML, Suzukawa K, Fukushima K.   +7 more
europepmc   +1 more source

The association between inborn errors of immunity and Hodgkin lymphoma—A register‐based case–control study in Sweden

British Journal of Haematology, EarlyView.
Summary Immune dysfunction is implicated in the aetiology of Hodgkin lymphoma (HL), but the association between inborn errors of immunity (IEI) and HL remains poorly understood. We conducted a retrospective, register‐based case–control study in Sweden over five decades to investigate the relationship between IEI and HL. Individuals diagnosed with HL in
Agnes Winsa, Ingemar Lagerlöf, Fredrik Ellin, Mats Fredriksson, Åsa Nilsdotter‐Augustinsson, Marcus Bendtsen, Jörg Cammenga, Sofia Nyström   +7 more
wiley   +1 more source

Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. [PDF]

CPT Pharmacometrics Syst Pharmacol
Bravo Padros M, Conrado DJ, Srinivasan K, Harnisch LO, Davis JD, Zhu M.   +5 more
europepmc   +1 more source